To determine the dose limiting toxicity and safety of bi-weekly courses of rBBX-01 in patients with resistant solid tumor malignancies.
To evaluate the pharmacokinetic and pharmacodynamics of bi-weekly rBBX-01. To correlate the inter-patient sensitivity to rBBX-01 with in vitro studies on patient blood. To describe any anti-tumor activity of rBBX-01.
18 Years and older (Adult, Senior)
March 26, 2009
July 15, 2013
Washington University School of Medicine St. Louis, Missouri, United States
† Study has passed its completion date and status has not been verified in more than two years.